Why Drug Safety Should Not Take a Back Seat to Efficacy by 
Editorial
Why Drug Safety Should Not Take a Back Seat to Efficacy
The PLoS Medicine Editors*
Historically, the evaluation of harmful
effects resulting from prescription drug use
has been considered less important than
demonstrating drug efficacy, yet the harms
caused by specific adverse drug reactions
are a major, and avoidable, contributor to
hospitalizations and deaths [1]. There are
many reasons (both scientific and social)
why reliable data on harmful effects may
only emerge well after drug approval and
marketing [2]. Some evidence suggests
that drugs approved under a rapid regu-
latory review process may be more likely
to show problems with safety post-market-
ing than drugs that go through a slower
evaluation process [3]. And debates con-
tinue about the best ways to meaningfully
synthesize and interpret data on the
possible harmful effects of drugs—for
example, how passive surveillance systems
(spontaneous reports of suspected adverse
reactions) should be improved, whether
new drugs should go through a phased
launch process with enhanced safety
evaluations, and whether risk mitigation
strategies are appropriate for drugs with
safety concerns.
One such debate—whether systematic
reviews estimating the risk of harmful
effects should use evidence from random-
ized trials or observational studies—seems
finally to have been laid to rest. In a
systematic overview published earlier this
year in PLoS Medicine [4], Su Golder, Yoon
Loke, and Martin Bland demonstrate that,
for 19 specific drug–harm relationships,
the evidence on magnitude of risk for each
particular harm discovered through sys-
tematic reviews of randomized trials was,
on average, no different from the evidence
assembled via systematic reviews of obser-
vational studies. This is an important
finding, although perhaps counterintuitive:
it is easy to imagine that observational
studies would be so plagued by confound-
ing that the estimates of risk of harm they
generate could be biased away from true
effects. The implications of this study for
future evaluations of drug safety are clear:
systematic reviewers should consider all
types of evidence in trying to build a
complete picture of harms associated with
drug treatments.
In another study published this week in
PLoS Medicine [5], Patricia McGettigan and
David Henry report their re-evaluation of
one specific and much-studied harmful
effect—that of cardiovascular risk associ-
ated with use of nonsteroidal anti-inflam-
matory drugs (NSAIDs). Many previous
systematic reviews have been conducted,
largely using evidence from randomized
trials, but these trials have generally
captured only small numbers of cardio-
vascular events and have focused mainly
on a small range of specific NSAIDs. By
revisiting observational data in their sys-
tematic review, Henry and colleagues
were able to form a fuller profile of the
cardiovascular risks associated with use of
a much wider group of NSAIDs, across
dose ranges and in population settings,
than had previously been the case. Broad-
ly, their findings correlate closely with
those of systematic reviews of trial data,
but also show that there seems to be no
‘‘safe’’ lower dose for cardiovascular risk
associated with certain NSAIDs, such as
rofecoxib and diclofenac.
These studies together highlight the
importance of data from high-quality
observational studies in enabling estima-
tion of the risk of harms associated with
specific drug treatments. Passive surveil-
lance is still crucial for providing early
warning signals and generating new hy-
potheses about possible harms associated
with specific approved drugs. However,
new hypotheses emerging from such
surveillance must subsequently be explic-
itly tested, preferably using study designs
that can incorporate data on the size of the
exposed population (such as cohort or
record linkage studies). Such studies can
therefore estimate the relative increase in
risk associated with exposure, which is
difficult or impossible to calculate from
passive surveillance data.
A new initiative established by the
European Medicines Agency (ENCEPP,
the European Network of Centres for
Pharmacoepidemiology and Pharmacov-
igilance [6,7]) seeks to promote the
conduct of such studies and establish
standards for post-marketing safety evalu-
ations. Given the diversity of designs and
multiple possible sources of bias in phar-
macoepidemiology, this will not be an easy
job. But the initiative is already showing
signs of setting high standards in some
areas. Studies conducted solely by industry
will not be eligible to qualify for ENCEPP
approval; studies must be publicly regis-
tered before collection of data, and
protocols and datasets must be released
(with some restrictions relating to data
privacy) in a timely way after completion.
Some vague wording in the ENCEPP
code of conduct remains, however: ‘‘data-
sets’’ can be interpreted to mean analyzed,
not raw, data, meaning that other inves-
tigators may not be able to exploit the full
potential of the data in conducting reanal-
yses. Critically, ENCEPP can still poten-
tially approve studies funded by the
pharmaceutical industry, with involve-
ment of industry partners in design and
analysis, providing the study’s lead inves-
tigator is based within an ENCEPP-
approved center. More worryingly, the
code allows for industry sponsors to retain
Citation: The PLoS Medicine Editors (2011) Why Drug Safety Should Not Take a Back Seat to Efficacy. PLoS
Med 8(9): e1001097. doi:10.1371/journal.pmed.1001097
Published September 27, 2011
Copyright:  2011 PLoS Medicine Editors. This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.
Funding: The authors are each paid a salary by the Public Library of Science, and they wrote this editorial
during their salaried time.
Competing Interests: The authors’ individual competing interests are at http://www.plosmedicine.org/static/
editorsInterests.action. PLoS is funded partly through manuscript publication charges, but the PLoS Medicine
Editors are paid a fixed salary (their salary is not linked to the number of papers published in the journal).
* E-mail: medicine_editors@plos.org
The PLoS Medicine Editors are Virginia Barbour, Jocalyn Clark, Susan Jones, Melissa Norton, Paul Simpson, and
Emma Veitch.
Provenance: Written by editorial staff; not externally peer reviewed.
PLoS Medicine | www.plosmedicine.org 1 September 2011 | Volume 8 | Issue 9 | e1001097control of datasets; this, and other provi-
sions, may enable conflicts of interest to
creep in during study design or data
analysis.
Clearly, for post-approval safety studies,
one size will not fit all. Conduct and
reporting are unlikely to be standardizable
in the same way as has been possible for
randomized trials, in which there is
agreement on what information needs to
be registered about the study and when
[8], and specific standards for the report-
ing of studies, such as CONSORT [9], are
widely accepted. The ENCEPP guidance
avoids normative statements about study
design, instead preferring to highlight the
methodological challenges and multiple
sources of bias that plague analysis and
interpretation of data. However, these
challenges should not discourage investi-
gators, regulators, and patients from
demanding a higher safety standard for
approved drugs. Higher standards will
require both greater transparency—in
revealing what studies are being conduct-
ed and what data that have been gener-
ated—and greater willingness of funders to
support new studies specifically addressing
drug safety.
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